Treatment on demand--in vivo dose finding studies.
Since the discovery of replacement therapy the goal of treatment for haemophilia patients has always been the prevention of haemorrhagic episodes. However, the "ideal"" plasma level needed to prevent hemathrosis or treat haemorrhages is still unknown. It seems that the doses of treatment have been arrived at by trial and error based in the pharmacokinetics of the factors and the characteristics of the replacement product. This review provides some guidelines for the treatment of haemophilia, however the doses are not based in randomized trials.
Escobar
M A
MA
Division of Hematology, University of Texas, Houston and the Gulf States Hemophilia and Thrombophilia Center, Houston, Texas 77030, USA. miguel.escobar@uth.tmc.edu
D004334:Drug Administration Schedule; D005164:Factor IX / Q000008:administration & dosage* / Q000493:pharmacokinetics; D005169:Factor VIII / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy*; D002836:Hemophilia B / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008297:Male
D005169:Factor VIII; D005164:Factor IX